Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Study of Allogeneic Low Oxygen Mesenchymal Bone Marrow Cells in Subjects With Myocardial Infarction

Conditions:   Myocardial Infarction With/Without ST Segment Elevation;   Allogeneic Low Oxygen Mesenchymal Bone Marrow Cells
Interventions:   Biological: Stem cells;   Other: Placebo
Sponsor:   Altaco XXI, LLP
Recruiting - verified February 2016

Danlou Tablets to Prevent Left Ventricular Remodeling

Conditions:   Left Ventricular Remodeling;   Acute Myocardial Infarction
Interventions:   Drug: Danlou Tablets;   Other: Placebo
Sponsor:   shuai Mao
Completed - verified February 2016

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Conditions:   Anemia;   Non-dialysis-dependent Chronic Kidney Disease
Interventions:   Drug: vadadustat;   Drug: darbepoetin alfa
Sponsor:   Akebia Therapeutics
Recruiting - verified February 2016

B-type Natriuretic Peptide Guided Therapy to Improve Clinical Outcomes for Patients Undergoing Non-cardiac Surgery

Conditions:   Surgery;   Cardiovascular Complications;   Risk Assessment
Intervention:   Other: BNP guided medical therapy optimisation
Sponsors:   University of KwaZulu;   University of Stellenbosch
Not yet recruiting - verified February 2016

Accelerated Rule Out of Myocardial Infarction

Condition:   Myocardial Infarction
Intervention:   Procedure: Accelerated, combined biomarker rule-out strategy for MI
Sponsor:   Aarhus University Hospital Skejby
Recruiting - verified February 2016

EXpanded CELL ENdocardiac Transplantation (EXCELLENT)

Condition:   Acute Myocardial Infarction
Interventions:   Drug: PROTHERACYTES;   Device: Standard of Care (Percutaneous Transluminal Coronary Angioplasty and stent(s) implantation)
Sponsor:   CellProthera
Recruiting - verified February 2016

Fractional FLow Reserve And IVUS for Clinical OUtcomes in Patients With InteRmediate Stenosis

Condition:   Stable Angina
Intervention:   Device: Drug-eluting stent
Sponsors:   Seoul National University Hospital;   Ajou University School of Medicine;   Keimyung University Dongsan Medical Center;   Inje University
Not yet recruiting - verified February 2016

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

Condition:   Thrombosis
Interventions:   Drug: BMS-986141;   Drug: Aspirin;   Other: Placebo
Sponsor:   Bristol-Myers Squibb
Not yet recruiting - verified January 2016

Sevoflurane and Percutaneous Coronary Intervention by Stent

Condition:   Myocardial Infarction
Intervention:   Drug: sevoflurane
Sponsor:   Instituto Dante Pazzanese de Cardiologia
Not yet recruiting - verified January 2016

Rivaroxaban ACS Specialist Cohort Event Monitoring Study

Condition:   Acute Coronary Syndrome
Intervention:   Other: This is a non-interventional study
Sponsor:   Drug Safety Research Unit, Southampton, UK
Recruiting - verified February 2016

Ticagrelor Versus Clopidogrel in Carotid Artery Stenting

Condition:   Carotid Artery Stenosis
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel;   Drug: Aspirin
Sponsor:   University Hospital, Basel, Switzerland
Not yet recruiting - verified February 2016

Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment (RIBS VI)

Condition:   Coronary In-stent Restenosis
Intervention:   Device: Bioresorbable vascular scaffold
Sponsors:   Spanish Society of Cardiology;   Hospital Universitario de la Princesa;   Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-IP);   Abbott Vascular;   St. Jude Medical;   Terumo Medical Corporation
Recruiting - verified January 2016

Knowledge Translation for Patients With Acute Coronary Syndromes

Condition:   Acute Coronary Syndromes
Intervention:   Behavioral: knowledge translation
Sponsors:   Montreal General Hospital;   Sanofi;   Canadian Institutes of Health Research (CIHR);   Fonds de la Recherche en Santé du Québec
Completed - verified January 2016

Mobilization of Endothelial Progenitor Cells and Aspirin

Condition:   Hypertrophic Obstructive Cardiomyopathy
Intervention:   Drug: Aspirin
Sponsor:   Ottawa Heart Institute Research Corporation
Not yet recruiting - verified January 2016

Hydroxychloroquine in Acute Coronary Syndrome: Prevention of Recurrent Cardiovascular Events (OXI)

Conditions:   Myocardial Infarction;   Acute Coronary Syndrome;   Inflammation;   Hydroxychloroquine;   Antirheumatic Agents;   Cardiovascular Diseases;   Angina, Unstable
Interventions:   Drug: Hydroxychloroquine;   Drug: Placebo
Sponsors:   Helsinki University Central Hospital;   Finnish Foundation for Cardiovascular Research;   Orion Corporation, Orion Pharma
Recruiting - verified February 2016

AZD9668, an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

Conditions:   Chronic Graft vs Host Disease;   Chronic Graft-Versus-Host-Disease;   Bronchiolitis Obliterans Syndrome
Intervention:   Drug: AZD9668
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified January 2016

Clinical Performance Evaluation of AQT90 FLEX TnI and TnT

Condition:   Myocardial Infarction
Intervention:  
Sponsor:   Radiometer Medical ApS
Recruiting - verified January 2016

GLP-1 and Hyperoxia for Organ Protection in Heart Surgery

Conditions:   Coronary Disease;   Shock, Cardiogenic;   Renal Failure;   Stroke;   Brain Injury;   Aortic Valve Disease
Interventions:   Drug: Byetta (Lilly, Exenatide);   Drug: Conoxia (AGA, oxygen);   Drug: 20% Human Albumin
Sponsor:   Rigshospitalet, Denmark
Not yet recruiting - verified February 2016

Evaluation of the Roadsaver Stent Used in Conjunction With the Nanoparasol Embolic Protection System for Carotid Artery Stenosis

Condition:   Carotid Artery Stenosis
Interventions:   Device: Roadsaver™ Carotid Artery Stent Device;   Device: Nanoparasol® Embolic Protection System
Sponsor:   Microvention-Terumo, Inc.
Not yet recruiting - verified February 2016

Evaluation of Intracoronary Hyperoxemic Oxygen Therapy in Anterior Acute Myocardial Infarction Patients (IC-HOT)

Condition:   Anterior Wall Acute Myocardial Infarction
Intervention:   Device: SSO2 Therapy
Sponsor:   TherOx
Recruiting - verified February 2016

Testing a Community Intervention to Increase Aspirin Use

Conditions:   Myocardial Infarction;   Stroke
Interventions:   Other: Mass Media plus clinic intervention.;   Other: Media
Sponsor:   University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified February 2016

EVOLVE Short DAPT Study

Condition:   Coronary Artery Disease
Interventions:   Drug: 3 months of dual antiplatelet therapy (DAPT);   Device: SYNERGY Stent System
Sponsor:   Boston Scientific Corporation
Recruiting - verified February 2016

Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy

Conditions:   Angina, Stable;   Angina, Unstable;   Anticoagulants
Interventions:   Device: COBRA PzF;   Device: DES
Sponsor:   CeloNova BioSciences, Inc.
Recruiting - verified February 2016

Burden of Illness in Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Drug: Standard of care in AF in Denmark
Sponsor:   Bayer
Completed - verified February 2016

NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction

Condition:   ST Elevation Myocardial Infarction
Interventions:   Drug: NP202;   Other: Placebo
Sponsor:   Armaron Bio Pty Ltd
Recruiting - verified February 2016

Optilene® Suture for Coronary Artery Bypass Graft Surgery

Conditions:   Coronary Heart Disease;   Multi Vessel Coronary Artery Disease
Intervention:   Procedure: Coronary Artery Bypass Graft surgery
Sponsors:   Aesculap AG;   B.Braun Surgical SA
Recruiting - verified January 2016

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Condition:   Peripheral Artery Disease
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban-Placebo
Sponsors:   Bayer;   Janssen Research & Development, LLC;   Colorado Prevention Center
Recruiting - verified February 2016

High-risk Patients in Cardiac Surgery Procedures: HiriSCORE

Condition:   C.Surgical Procedure; Cardiac
Intervention:  
Sponsors:   University of Sao Paulo General Hospital;   InCor Heart Institute;   Cardiology Institute of the Distrito Federal, Brazil;   Clinical Hospital Samuel Libânio of Pouso Alegre, Brazil;   Beneficência Portuguesa of São Paulo, Brazil;   Hospital Clínico Universitario de Valladolid;   National Institute of Cardiology, Laranjeiras, Brazil;   Russian Cardiology Research and Production Center, Russian;   La Princesa University Hospital Madrid, Spain;   TotalCor Hospital, Brazil;   Royal Adelaide Hospital;   Santa Casa de Misericórdia of Marília, Brazil;   Hospital de Base
Active, not recruiting - verified June 2015

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Recruiting - verified January 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsor:   Bayer
Recruiting - verified February 2016

A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction

Condition:   Heart Failure
Interventions:   Drug: BAY1142524;   Drug: BAY1142524;   Drug: BAY1142524;   Drug: BAY1142524;   Drug: Placebo
Sponsor:   Bayer
Active, not recruiting - verified February 2016

Profile and Antithrombotic Management of Patients With NVAF Attending Internal Medicine Departments in Spain (PERFILAR Study)

Condition:   Anticoagulation, Blood Thinners , Atrial Fibrillation, Bleeding, Stroke
Intervention:  
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified February 2016

A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection

Condition:   Asthma
Interventions:   Drug: Interferon beta-1a Nebuliser solution 48 μg/mL;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified February 2016

Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis

Condition:   Aortic Stenosis
Intervention:   Procedure: surgical aortic valve replacement
Sponsor:   Clinical Centre of Serbia
Recruiting - verified February 2016

Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Recruiting - verified February 2016

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Condition:   Cost Sharing, Acute Coronary Syndrome,
Intervention:   Other: Study voucher card
Sponsors:   AstraZeneca;   Duke Clinical Research Institute
Recruiting - verified January 2016

The RESTORE-SIRIO Randomized Controlled Trial

Conditions:   Percutaneous Coronary Intervention;   No-reflow Phenomen;   Acute ST-segment Elevation Myocardial Infarction
Interventions:   Other: intracoronary epinephrine;   Other: no intracoronary epinephrine
Sponsors:   Heinrich-Heine University, Duesseldorf;   SIRIO MEDICINE
Withdrawn - verified February 2016

COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial

Condition:   ST Elevation Acute Myocardial Infarction
Interventions:   Drug: Exenatide;   Other: Remote Ischemic Conditioning (RIC);   Drug: Placebo
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Not yet recruiting - verified January 2016

Brilinta Taiwan Post Approval Safety Study

Condition:   Non ST-elevation Myocardial Infarction
Intervention:   Drug: Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
Sponsor:   AstraZeneca
Recruiting - verified February 2016

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

Conditions:   Coronary Artery Disease;   Atherosclerosis, Coronary;   Myocardial Ischemia;   Ischemic Heart Disease;   Acute Coronary Syndrome;   Angina Pectoris
Interventions:   Device: Orsiro DES;   Device: Xience DES
Sponsors:   Biotronik, Inc.;   Biotronik AG;   Harvard Clinical Research Institute;   Medstar Research Institute
Recruiting - verified February 2016

Prevention of Myocardial Injury in Non-cardiac Surgery

Conditions:   Myocardial Injury;   Myocardial Infarction
Intervention:   Procedure: Remote ischemic preconditioning
Sponsor:   University Hospital Koge
Recruiting - verified February 2016

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Conditions:   HIV Infections;   Cardiovascular Diseases
Interventions:   Drug: Pitavastatin;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Kowa Pharmaceuticals America, Inc.
Recruiting - verified February 2016

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
Interventions:   Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified December 2015

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Condition:   Stroke
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin (Acetylsalicylic acid, BAY1019036);   Other: Rivaroxaban-Placebo;   Other: Aspirin-Placebo
Sponsors:   Bayer;   Janssen, LP;   Hamilton Health Sciences Cooperation, Population Health Research Institute
Recruiting - verified February 2016

A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction

Conditions:   Heart Attack;   NSTEMI
Interventions:   Biological: AMI MultiStem cells;   Other: Sham
Sponsors:   Athersys, Inc;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2016

Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery

Condition:   Myocardial Injury
Interventions:   Drug: ticagrelor;   Drug: aspirin
Sponsors:   The Cleveland Clinic;   AstraZeneca
Recruiting - verified January 2016

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Conditions:   Stroke;   Secondary Prevention
Interventions:   Drug: optional ASA as comedication;   Drug: placebo to ASA;   Drug: placebo to optional ASA as comedication;   Drug: placebo to dabigatran etexilate;   Drug: ASA 100 mg;   Drug: dabigatran etexilate
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

Exercise as a Life-long Medicine in Patients With Coronary Artery Disease

Conditions:   Cardiovascular Diseases;   Myocardial Infarction;   Angina (Stable)
Interventions:   Behavioral: high-intensity exercise training;   Behavioral: web-based follow-up program;   Behavioral: usual care
Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital;   Levanger Hospital
Recruiting - verified February 2016

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2016

Circadian Rhythms and Cardiovascular Risk

Condition:   Obstructive Sleep Apnea
Intervention:   Behavioral: Forced Desynchrony
Sponsor:   Oregon Health and Science University
Recruiting - verified January 2016

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Epoetin alfa
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2016

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis.

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2016

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: Dabigatran Etexilate 110mg;   Drug: Warfarin 3mg;   Drug: Aspirin;   Drug: Dabigatran Etexilate 150mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 5mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 1mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

Absorb IV Randomized Controlled Trial

Conditions:   Coronary Artery Disease;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Stenosis
Interventions:   Device: Absorb BVS;   Device: XIENCE
Sponsor:   Abbott Vascular
Recruiting - verified February 2016

Multidetector Coronary CT In Vasospastic Angina

Condition:   Vasospastic Angina
Interventions:   Procedure: Positive CAG with EG test;   Procedure: Negative CAG with EG test
Sponsor:   Dong-A University
Recruiting - verified February 2016

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Losmapimod 7.5 mg twice daily;   Drug: Placebo twice daily
Sponsors:   GlaxoSmithKline;   The TIMI Study Group
Recruiting - verified January 2016

Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction

Conditions:   Myocardial Infarction;   Percutaneous Coronary Intervention;   Thrombolytic Therapy
Interventions:   Drug: Prourokinase;   Drug: Tirofiban;   Drug: normal saline
Sponsor:   Fudan University
Recruiting - verified February 2016

The Short- and Long Term Outcomes of Early Routine PCI With the Standard Treatment in Low-intermediate Risk ST-elevation Myocardial Infarction Patients Who Successfully Fibrinolysis.

Condition:   ST-elevation Myocardial Infarction
Intervention:   Other: Percutaneous coronary intervention
Sponsor:   Chiang Mai University
Completed - verified May 2014

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Condition:   Acute Myocardial Infarction
Interventions:   Biological: CSL112;   Biological: Placebo
Sponsor:   CSL Behring
Active, not recruiting - verified February 2016

Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Treatment 90 days DAPT;   Drug: Treatment 360 days DAPT
Sponsor:   Diagram B.V.
Recruiting - verified February 2016

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Conditions:   Pulmonary Embolism;   Thromboembolism;   Thrombosis;   Venous Thrombosis;   Venous Thromboembolism
Interventions:   Drug: BAY 59-7939;   Drug: BAY 59-7939;   Drug: ASA
Sponsor:   Bayer
Recruiting - verified February 2016

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

Condition:   Atrial Fibrillation
Intervention:   Drug: Observational
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

Ventricular Remodeling and Heart Failure After Myocardial Infarction: A Community Study

Conditions:   Heart Failure;   Myocardial Infarction
Intervention:  
Sponsor:   Mayo Clinic
Recruiting - verified February 2016

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Condition:   Atrial Fibrillation
Interventions:   Drug: Apixaban;   Drug: Parenteral heparin and/or oral Vitamin K antagonist
Sponsors:   Pfizer;   Bristol-Myers Squibb
Recruiting - verified February 2016

Reduction in Infarct Size by Remote Per-postconditioning in Patients With ST-elevation Myocardial Infarction

Conditions:   Coronary Artery Disease;   Myocardial Infarction
Intervention:   Procedure: Primary Percutaneous Coronary Intervention
Sponsor:   John Pernow
Completed - verified February 2016

Evaluation of Goal-Directed Intraoperative Hemodynamic Optimization Protocol

Condition:   Postoperative Complications
Intervention:  
Sponsor:   University of California, Irvine
Recruiting - verified February 2016

Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury

Condition:   Acute Myocardial Infarction
Interventions:   Drug: liraglutide (Novo Nordisk, Bagsværd, Denmark);   Drug: liraglutide placebo (Novo Nordisk)
Sponsor:   Chen Wei Ren, MD
Recruiting - verified February 2016

Essential Hypotension and Adaptability Registry

Conditions:   Blood Pressure;   Depression;   Panic Attack;   Fibromyalgia;   POTS;   Inappropriate Sinus Tachycardia;   Coronary Heart Disease;   Acute Coronary Syndrome (ACS);   Acute Myocardial Infarction (AMI);   Cerebrovascular Disease (CVD);   Transient Ischemic Attack (TIA);   Atrial Fibrillation;   Diabetes Mellitus;   Cancer;   Systolic Heart Failure;   Diastolic Heart Failure;   Chronic Fatigue Syndrome;   Syncope;   Vasovagal Syncope
Intervention:  
Sponsor:   CES University
Recruiting - verified February 2016

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Ticagrelor 60 mg;   Drug: Ticagrelor placebo
Sponsor:   AstraZeneca
Recruiting - verified February 2016

The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation

Conditions:   Antibody-mediated Rejection;   Hyperacute Rejection of Cardiac Transplant;   Left Ventricular Dysfunction;   Cardiac Allograft Vasculopathy;   Heart Graft Dysfunction
Intervention:   Drug: Eculizumab
Sponsors:   Cedars-Sinai Medical Center;   Alexion Pharmaceuticals
Enrolling by invitation - verified February 2016

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

Conditions:   Breast Cancer;   Breast Tumors;   Cancer of Breast
Interventions:   Drug: Metformin;   Drug: Atorvastatin;   Procedure: Breast surgery
Sponsor:   Columbia University
Recruiting - verified February 2016

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified February 2016

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified February 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsor:   Bayer
Recruiting - verified February 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2016

Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

Conditions:   Atrial Fibrillation;   Stroke
Interventions:   Drug: Apixaban;   Drug: aspirin
Sponsors:   Population Health Research Institute;   Bristol-Myers Squibb;   Pfizer;   Medtronic
Recruiting - verified February 2016

Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)

Condition:   HIV-1 Infection
Intervention:   Drug: Telmisartan
Sponsors:   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting - verified January 2016

A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)

Conditions:   Coronary Artery Disease;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Stenosis
Interventions:   Device: XIENCE V EECSS;   Device: ABSORB BVS System
Sponsor:   Abbott Vascular
Active, not recruiting - verified January 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2016

A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)

Condition:   Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Withdrawn - verified February 2016

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Condition:   Prevention & Control
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Sponsors:   Bayer;   Hamilton Health Sciences Corporation, Population Health Research Institute
Recruiting - verified February 2016

ABSORB FIRST is a Registry Designed to Evaluate the Safety and Performance of Absorb Bioresorbable Vascular Scaffold (Absorb BVS) Used in Real-world Patients.

Conditions:   Chronic Total Occlusion of Coronary Artery;   Coronary Occlusion;   Coronary Artery Disease;   Coronary Artery Restenosis;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Restenosis
Intervention:   Device: Absorb Bioresorbable Vascular Scaffold
Sponsor:   Abbott Vascular
Completed - verified January 2016

Optical Frequency Domain Imaging (OFDI) and Vascular Healing After Stent Placement Diabetics Presenting With Acute Coronary Syndrome

Condition:   Coronary Artery Disease
Intervention:   Device: Resolute Integrity stent
Sponsor:   Emory University
Active, not recruiting - verified February 2016

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition:   Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab;   Drug: placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified February 2016

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified January 2016

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Condition:   Hodgkin Lymphoma, Adult
Interventions:   Drug: Brentuximab vedotin;   Drug: ABVD
Sponsors:   UNC Lineberger Comprehensive Cancer Center;   Seattle Genetics, Inc.
Suspended - verified February 2016

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Coronary Artery Disease;   Heart Diseases;   Myocardial Ischemia
Interventions:   Procedure: cardiac catheterization;   Procedure: coronary artery bypass graft surgery;   Procedure: percutaneous coronary intervention;   Behavioral: Lifestyle;   Drug: Medication
Sponsors:   New York University School of Medicine;   New York University;   Stanford University;   National Heart, Lung, and Blood Institute (NHLBI);   Albany Stratton VA Medical Center;   Cedars-Sinai Medical Center;   Columbia University;   Duke University;   East Carolina University;   Emory University;   Harvard University;   Massachusetts General Hospital;   Montreal Heart Institute;   University of British Columbia;   University of Missouri, Kansas City;   Vanderbilt University
Recruiting - verified January 2016

Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation

Condition:   HIV-1 Infection
Interventions:   Drug: Pravastatin sodium;   Drug: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate;   Drug: Pravastatin sodium
Sponsors:   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Withdrawn - verified January 2016

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

Study of the Natural History of FFR Guided Percutaneous Coronary Intervention

Condition:   Coronary Artery Disease
Intervention:  
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea;   St. Jude Medical (Hong Kong) Limited
Recruiting - verified February 2016

Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock

Condition:   Cardiogenic Shock
Intervention:   Drug: epinephrine/norepinephrine
Sponsor:   Central Hospital, Nancy, France
Recruiting - verified February 2016

The Natural History of Graft-Versus-Host Disease in the Eyes

Condition:   Graft-Versus-Host Disease
Intervention:  
Sponsor:   National Eye Institute (NEI)
Completed - verified February 2016

A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

Condition:   Myocardial Infarction
Interventions:   Procedure: Percutaneous Coronary Intervention (PCI);   Drug: RO4905417;   Drug: RO4905417;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Remote Ischemic Preconditioning in High Risk Cardiovascular Surgery Patients

Conditions:   Death;   Stroke;   Low Cardiac Output Syndrome;   Myocardial Infarction;   Renal Failure;   Pulmonary Failure
Interventions:   Other: Remote ischemic preconditioning stimulus;   Other: control
Sponsor:   Queen's University
Completed - verified February 2016

Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans

Conditions:   Bronchiolitis Obliterans;   Graft vs Host Disease
Intervention:   Drug: Cyclosporine Inhalation Solution
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified October 2015

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement

Condition:   Severe Aortic Stenosis
Interventions:   Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI);   Device: Surgical Aortic Valve Replacement (SAVR)
Sponsor:   Medtronic Cardiovascular
Active, not recruiting - verified January 2016

Morphine In Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Drug: morphine chlorhydrate;   Drug: saline solution
Sponsors:   French Cardiology Society;   Institut National de la Santé Et de la Recherche Médicale, France
Active, not recruiting - verified February 2016

Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty

Condition:   Saphenous Vein Graft Atherosclerosis
Interventions:   Device: Bare Metal Stent;   Device: Drug-Eluting Stent;   Drug: Blinded clopidogrel;   Drug: Placebo;   Drug: Thienopyridine (open-label)
Sponsor:   VA Office of Research and Development
Active, not recruiting - verified February 2016

The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository

Condition:   Homozygous Familial Hypercholesterolemia
Intervention:  
Sponsor:   The Rogosin Institute
Recruiting - verified February 2016

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients

Conditions:   Medication Non-adherence;   Stent Thrombosis
Intervention:  
Sponsors:   Icahn School of Medicine at Mount Sinai;   Bristol-Myers Squibb;   Sanofi
Completed - verified February 2016

Comparison of Cardiac Computed Tomography and Vasodilator Stress Magnetic Resonance Imaging Perfusion in Patients With Prior Equivocal Stress Test for Detection of Coronary Artery Disease

Conditions:   Myocardial Ischemia;   Coronary Artery Disease;   Myocardial Infarction
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2016

Autologous Cell Therapy After Stroke

Condition:   Stroke
Interventions:   Biological: autologous bone marrow mononuclear cell transfusion;   Biological: marrow stromal cells;   Drug: placebo
Sponsors:   University of California, Irvine;   University of California, San Diego
Withdrawn - verified February 2016

Ventricular Tachycardia (VT) Ablation Versus Enhanced Drug Therapy

Condition:   Recurrent Ventricular Tachycardia
Interventions:   Procedure: Catheter Ablation;   Drug: Aggressive Antiarrhythmic Therapy (Amiodarone)
Sponsors:   John Sapp;   St. Jude Medical;   Biosense Webster, Inc.;   Canadian Institutes of Health Research (CIHR)
Completed - verified January 2016

Safety and Efficacy of SeeMore (TM) in Heart Patients

Condition:   Myocardial Infarction
Intervention:   Drug: SeeMore(TM)
Sponsor:   Eagle Vision Pharmaceutical Corp.
Completed - verified February 2016

Polycystic Kidney Disease Data Repository

Condition:   Polycystic Kidney Disease
Intervention:  
Sponsors:   The Rogosin Institute;   Weill Medical College of Cornell University;   New York Presbyterian Hospital
Recruiting - verified February 2016

A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.

Condition:   Anemia
Interventions:   Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta);   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
Sponsor:   Hoffmann-La Roche
Active, not recruiting - verified February 2016

Study of Ambrisentan in Subjects With Pulmonary Hypertension

Condition:   Pulmonary Hypertension
Intervention:   Drug: Ambrisentan
Sponsor:   Gilead Sciences
Active, not recruiting - verified January 2016

Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer

Condition:   Breast Neoplasms
Intervention:   Drug: Th2/Tc2 Cells
Sponsor:   National Cancer Institute (NCI)
Completed - verified August 2013

Vascular Interaction With Age in Myocardial Infarction

Condition:   Myocardial Infarction
Intervention:   Drug: L-Arginine
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified November 2005

Multi-Ethnic Study of Atherosclerosis (MESA) - Ancillary Eye Study

Conditions:   Atherosclerosis;   Cardiovascular Diseases;   Coronary Arteriosclerosis;   Coronary Disease;   Cerebrovascular Disorders;   Heart Failure, Congestive;   Myocardial Infarction;   Heart Diseases;   Diabetes Mellitus, Non-insulin Dependent;   Hypertension;   Diabetic Retinopathy;   Macular Degeneration;   Diabetes Mellitus
Intervention:  
Sponsors:   University of Wisconsin, Madison;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2016

Natural History of Stroke: Cause and Development

Conditions:   Nervous System Disease;   Transient Ischemic Attack;   Neurologic Disorders;   Stroke;   Vascular Disease
Intervention:  
Sponsor:   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified June 2015

Minnesota Heart Survey - Mortality and Morbidity

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases;   Myocardial Infarction;   Death, Sudden, Cardiac
Intervention:  
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2016

Effect of Drug Therapy on Reinfarction Risk in Women

Conditions:   Cardiovascular Diseases;   Myocardial Infarction;   Heart Diseases
Intervention:  
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified April 2001

Postmenopausal Progestins, MI and Stroke

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Coronary Disease;   Cerebrovascular Accident;   Myocardial Infarction;   Postmenopause
Intervention:  
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified June 2000

Homocyst(e)Ine, Vitamin Status, and CVD Risk

Conditions:   Cardiovascular Diseases;   Cerebrovascular Accident;   Coronary Disease;   Myocardial Infarction;   Heart Diseases;   Hyperhomocysteinemia
Intervention:  
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified June 2000

Epidemiology of Coronary Heart Disease in Blacks

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Coronary Disease;   Myocardial Infarction
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified May 2000

Common Variants in Candidate Genes and Premature MI Risk

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Myocardial Infarction
Intervention:  
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified January 2005

Mediators of Social Support in Coronary Disease

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases;   Myocardial Infarction;   Depression
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified August 2004

Novel Hemostatic Cardiac Risk Factors in Framingham

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Death, Sudden, Cardiac;   Myocardial Infarction;   Thrombosis;   Atherosclerosis;   Carotid Artery Diseases
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified March 2005

Minnesota Heart Survey - Risk Factor Survey

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Cerebrovascular Accident;   Coronary Disease;   Hypertension;   Myocardial Infarction
Intervention:  
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2016

Myocardial Infarction Triage and Intervention Project (MITI)

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases;   Myocardial Infarction;   Myocardial Ischemia
Intervention:   Drug: tissue plasminogen activator
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified June 2001

Intravenous Streptokinase in Acute Myocardial Infarction

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases;   Myocardial Infarction;   Myocardial Ischemia
Intervention:   Drug: streptokinase
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified October 1994